MTOR and neoplasm: Selective activation of TNFR2 drives ccRCC tumor cell proliferation by a signaling pathway involving cytosolic endothelial/epithelial tyrosine kinase–mediated activation of vascular endothelial cell growth factor receptor type 2, phosphatidylinositol-3-kinase (PI3K), Akt, and the mammalian target of rapamycin (mTOR).5